Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)
Omeros (OMER) reported Total Non-Current Liabilities of $202.1 million for Q1 2026, down 12.36% on a YoY basis from $230.7 million in Q1 2025, and up 20.0% sequentially from $168.5 million in Q4 2025.
Omeros (OMER) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Omeros (OMER) has 6 years of Total Non-Current Liabilities data on file, last reported at $202.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 12.36% year-over-year to $202.1 million; the trailing twelve-month figure through Mar 2026 stood at $202.1 million (down 12.36% YoY), and the FY2025 full-year result was $168.5 million, down 38.2% from the prior year.
- Total Non-Current Liabilities grew to $202.1 million in Q1 2026, from $168.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $590.5 million in Q4 2022 to a low of $168.5 million in Q4 2025.
- A 5-year average of $356.9 million and a median of $354.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 52.88% in 2023 and plunged 47.02% in 2025, its largest moves.
- Tracing OMER's Total Non-Current Liabilities over 5 years: stood at $590.5 million in 2022, then slumped by 36.3% to $376.2 million in 2023, then dropped by 27.54% to $272.6 million in 2024, then slumped by 38.2% to $168.5 million in 2025, then climbed by 20.0% to $202.1 million in 2026.
- Business Quant data shows OMER's Total Non-Current Liabilities at $202.1 million in Q1 2026, $168.5 million in Q4 2025, and $181.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 202.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202.15 Mn |
| Dec 31, 2025 | 168.46 Mn |
| Sep 30, 2025 | 181.21 Mn |
| Jun 30, 2025 | 196.07 Mn |
| Mar 31, 2025 | 230.66 Mn |
| Dec 31, 2024 | 272.58 Mn |
| Sep 30, 2024 | 310.24 Mn |
| Jun 30, 2024 | 354.23 Mn |
| Mar 31, 2024 | 435.40 Mn |
| Dec 31, 2023 | 376.18 Mn |
| Sep 30, 2023 | 493.07 Mn |
| Jun 30, 2023 | 526.93 Mn |
| Mar 31, 2023 | 559.68 Mn |
| Dec 31, 2022 | 590.53 Mn |
| Sep 30, 2022 | 456.55 Mn |
| Jun 30, 2022 | 344.68 Mn |
| Mar 31, 2022 | 368.34 Mn |
| Dec 31, 2021 | 418.15 Mn |